Prognostic value of MICA/B in cancers: a systematic review and meta-analysis

Yijing Zhao; Naifei Chen; Yu Yu; Lili Zhou; Chao Niu; Yudi Liu; Huimin Tian; Zheng Lv; Fujun Han; Jiuwei Cui

doi:10.18632/oncotarget.21466

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Prognostic value of MICA/B in cancers: a systematic review and meta-analysis

Yijing Zhao, Naifei Chen, Yu Yu, Lili Zhou, Chao Niu, Yudi Liu, Huimin Tian, Zheng Lv, Fujun Han and Jiuwei Cui _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:96384-96395. https://doi.org/10.18632/oncotarget.21466

Metrics: PDF 2130 views | HTML 3348 views | ?

Abstract

Yijing Zhao1, Naifei Chen1, Yu Yu1, Lili Zhou1, Chao Niu1, Yudi Liu1, Huimin Tian1, Zheng Lv1, Fujun Han1 and Jiuwei Cui1

1Cancer Center, The First Hospital of Jilin University, Changchun, 130021, China

Correspondence to:

Jiuwei Cui, email: [email protected]

Keywords: MICA, MICB, prognosis, cancer, meta-analysis

Received: August 02, 2017 Accepted: September 22, 2017 Published: October 03, 2017

ABSTRACT

Purpose: MHC class I chain related-proteins A (MICA) and B (MICB) are natural killer group 2D ligands that mediate tumor surveillance. Several studies have suggested that MICA/B levels predict clinical outcomes in patients with cancer; however, this remains contentious. Here, we present a systematic review and meta-analysis of available studies of the prognostic value of MICA/B in cancer.

Materials and Methods: We searched PubMed, Embase, Clinicaltrials.gov, and Cochrane Library to identify studies published from inception to July 2017 that assessed MICA/B in patients with cancer. The hazard ratio (HR) and 95% confidence interval (CI) of MICA/B were extracted for overall survival (OS) analysis.

Results: A total of 19 studies comprising 2,588 patients with 10 different types of cancer were included in the study. Low sMICA/B levels were found associated with significantly longer OS (HR = 1.65, 95% CI [1.42–1.92], P < 0.00001). Patients with cancers of digestive system that exhibited high MICA/B expression had significantly longer OS in (HR = 0.56, 95% CI [0.39–0.80], P = 0.002) compared with those with lower MICA/B expression (I² = 35%, P = 0.18).

Conclusions: Serum soluble MICA/B represents a potential prognostic marker in various human cancers. High cell-surface MICA/B expression in cancers of the digestive system was found associated with increased survival.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21466

Publication Alerts

Meta-Analysis:

Prognostic value of MICA/B in cancers: a systematic review and meta-analysis

Abstract